Randomized comparison of Ticagrelor versus prasugrel in patients with acute coronary syndrome and planned invasive strategy - Design and rationale of the intracoronary stenting and antithrombotic regimen: Rapid early action for coronary treatment (ISAR-REACT) 5 trial

Journal of Cardiovascular Translational Research

Volumn 7, Issue 1, 2014, Pages 91-100

  Schulz, Stefanie ^a   Angiolillo, Dominick J ^b   Antoniucci, David ^c   Bernlochner, Isabell ^d   Hamm, Christian ^e,i   Jaitner, Juliane ^d   Laugwitz, Karl Ludwig ^d,i   Mayer, Katharina ^a   Von Merzljak, Barbara ^a   Morath, Tanja ^a   Neumann, Franz Josef ^f   Richardt, Gert ^g   Ruf, Judith ^a   Schömig, Gisela ^a   Schühlen, Helmut ^h   Schunkert, Heribert ^a,i   Kastrati, Adnan ^a,i  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e KERCKHOFF HEART CENTER   (Germany)

^f UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^g Herzzentrum der Segeberger Kliniken   (Germany)

^h Vivantes   (Germany)

ⁱ DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

Acute coronary syndrome; PCI; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; PRASUGREL; TICAGRELOR;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; CORONARY STENT; DRUG EFFICACY; HUMAN; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION;

ACUTE CORONARY SYNDROME; ADENOSINE; CLINICAL PROTOCOLS; CORONARY THROMBOSIS; DRUG ADMINISTRATION SCHEDULE; FIBRINOLYTIC AGENTS; GERMANY; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET AGGREGATION INHIBITORS; RESEARCH DESIGN; STENTS; STROKE; THIOPHENES; TIME FACTORS; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 84896708052     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9527-3     Document Type: Article

References (34)

1. Schomig, A., Neumann, F. J., Kastrati, A., et al. (1996). A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. The New England Journal of Medicine, 334, 1084-1089.
2. Hamm, C. W., Bassand, J. P., Agewall, S., et al. (2011). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). European Heart Journal, 32, 2999-3054.
3. Task Force on the management of STseamiotESoC, Steg, P. G., James, S. K., et al. (2012). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. European Heart Journal, 33, 2569-2619.
4. Kushner, F. G., Hand, M., Smith, S. C., Jr., et al. (2009). 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 54, 2205-2241.
5. Levine, G. N., Bates, E. R., Blankenship, J. C., et al. (2011). 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Journal of the American College of Cardiology, 58, e44-e122.
6. Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O'Connor, C. M. (2003). Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation, 107, 2908-2913.
7. Serebruany, V. L., Steinhubl, S. R., Berger, P. B., Malinin, A. I., Bhatt, D. L., & Topol, E. J. (2005). Variability in platelet responsiveness to clopidogrel among 544 individuals. Journal of the American College of Cardiology, 45, 246-251.
8. Bonello, L., Tantry, U. S., Marcucci, R., et al. (2010). Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. Journal of the American College of Cardiology, 56, 919-933.
9. Wiviott, S. D., Braunwald, E., McCabe, C. H., et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357, 2001-2015.
10. Wallentin, L., Becker, R. C., Budaj, A., et al. (2009). Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 361, 1045-1057.
11. Brandt, J. T., Payne, C. D., Wiviott, S. D., et al. (2007). A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. American Heart Journal, 153(66), 9-16.
12. Gurbel, P. A., Bliden, K. P., Butler, K., et al. (2009). Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation, 120, 2577-2585.
13. Sugidachi, A., Asai, F., Ogawa, T., Inoue, T., & Koike, H. (2000). The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties. British Journal of Pharmacology, 129, 1439-1446.
14. Husted, S., Emanuelsson, H., Heptinstall, S., Sandset, P. M., Wickens, M., & Peters, G. (2006). Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. European Heart Journal, 27, 1038-1047.
15. Wallentin, L. (2009). P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. European Heart Journal, 30, 1964-1977.
16. Schomig, A. (2009). Ticagrelor - is there need for a new player in the antiplatelet-therapy field? The New England Journal of Medicine, 361, 1108-1111.
17. Steg, P. G., James, S., Harrington, R. A., et al. (2010). Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation, 122, 2131-2141.
18. Montalescot, G., Wiviott, S. D., Braunwald, E., et al. (2009). Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet, 373, 723-731.
19. Montalescot, G., Bolognese, L., Dudek, D., et al. (2011). A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction: design and rationale for the ACCOAST study. American Heart Journal, 161, 650-656. e1.
20. Montalescot, G., Bolognese, L., Dudek, D., et al. (2013). Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. New England Journal of Medicine, 369, 999-1010.
21. Roe, M. T., Armstrong, P. W., Fox, K. A., et al. (2012). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. The New England Journal of Medicine, 367, 1297-1309.
22. James, S. K., Roe, M. T., Cannon, C. P., et al. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ, 342, d3527.
23. Held, C., Asenblad, N., Bassand, J. P., et al. (2011). Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology, 57, 672-684.
24. Headrick, J. P., Peart, J. N., Reichelt, M. E., & Haseler, L. J. (1808). Adenosine and its receptors in the heart: regulation, retaliation and adaptation. Biochimica et Biophysica Acta, 2011, 1413-1428.
25. Serebruany, V. L. (2011). Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical outcomes trial? American Heart Journal, 161, 1-4.
26. Ohman, J., Kudira, R., Albinsson, S., Olde, B., & Erlinge, D. (2012). Ticagrelor induces adenosine triphosphate release from human red blood cells. Biochemical and Biophysical Research Communications, 418, 754-758.
27. Björkman JA, K. I., & van Giezen, J. J. J. (2007). AZD6140 inhibits adenosine uptake into erythrocytes and enhances coronary blood flow after local ischemia or intracoronary adenosine infusion. Circulation, 116(II), 28. Abstract 245.
28. van Giezen, J. J., Sidaway, J., Glaves, P., Kirk, I., & Bjorkman, J. A. (2012). Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. Journal of Cardiovascular Pharmacology and Therapeutics, 17, 164-172.
29. Wittfeldt, A., Emanuelsson, H., Brandrup-Wognsen, G., et al. (2013). Ticagrelor enhances adenosine-induced coronary vasodilatory responses in humans. Journal of the American College of Cardiology, 61(7), 723-7. doi: 10.1016/j.jacc.2012.11.032.
30. Mehran, R., Rao, S. V., Bhatt, D. L., et al. (2011). Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation, 123, 2736-2747.
31. Cutlip, D. E., Windecker, S., Mehran, R., et al. (2007). Clinical end points in coronary stent trials: a case for standardized definitions. Circulation, 115, 2344-2351.
32. Thygesen, K., Alpert, J. S., Jaffe, A. S., et al. (2012). Third universal definition of myocardial infarction. European Heart Journal, 33, 2551-2567.
33. Wiviott, S. D., White, H. D., Ohman, E. M., et al. (2013). Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial. Lancet, 382, 605-613.
34. Sarafoff, N., Martischnig, A., Wealer, J., et al. (2013). Triple therapy with aspirin, prasugrel, and vitamin k antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. Journal of the American College of Cardiology, 61, 2060-2066.